早期阿达木单抗血清水平对未经抗TNF治疗的克罗恩病患者免疫原性及长期结局的影响:快速检测的实用性
研究前瞻性纳入116例活动性、未经生物制剂治疗的克罗恩病患者,在第0、4、12周采集血清,用RIDA® QUICK侧流法测阿达木单抗水平、耐药法测抗药抗体。第4周水平低(<8.3 μg/mL)者第12周抗药抗体阳性率显著更高(46.7% vs 13.0%,P=0.009)。中位随访89周,37.1%需加量、48.3%获持续临床获益。
要点
- 第4周阿达木单抗<8.3 μg/mL者第12周抗药抗体阳性率46.7% vs 13.0%(P=0.009)。
- 第12周抗药抗体阳性者占21.4%,加量需求更高(P<0.001),持续临床获益更少(P=0.02)。
- 中位随访89周,37.1%患者需加量、48.3%获持续临床获益。
核心结论
- 作者认为研究结果支持早期监测阿达木单抗血清水平以指导剂量优化,可能预防免疫原性并影响长期结局。
- 作者验证了一种新型侧流法可定量测定阿达木单抗水平,便于医生在门诊即时优化治疗。
研究设计与样本
- 前瞻性收集116例活动性、未经生物制剂治疗的克罗恩病患者基线及第4、12周血清样本。
- 用RIDA® QUICK阿达木单抗侧流法测血清水平,用耐药法测抗阿达木单抗药物抗体。
- 第12周前因症状持续停用阿达木单抗者视为原发性无应答,第12周后初始改善再加重视为继发性失应答,随访至末次仍继续用药视为持续临床获益。
主要发现
- 第4周血清水平低(<8.3 μg/mL)者第12周抗阿达木单抗抗体阳性风险显著更高(46.7% vs 13.0%,P=0.009)。
- 中位随访89周,37.1%患者需加量、48.3%患者获持续临床获益。
- 第12周抗阿达木单抗抗体阳性者占21.4%,其加量需求显著更高(P<0.001),因原发性无应答或继发性失应答而获持续临床获益更少(P=0.02)。
临床怎么用
- 作者认为早期监测阿达木单抗血清水平可指导剂量优化,可能预防免疫原性并影响长期结局。
- 作者验证的侧流法可定量测定阿达木单抗水平,便于医生在门诊即时优化治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Proactive testing of adalimumab serum levels is debated. AIM: To study the association between adalimumab serum levels at week 4 and the development of anti-adalimumab drug antibodies and long-term outcome in anti-TNF naive Crohn's disease patients. METHODS: Serum samples from 116 biologically naive Crohn's disease patients with active disease were prospectively collected at baseline, and weeks 4 and 12. Adalimumab serum levels were measured using the RIDA® QUICK adalimumab lateral flow assay and anti-adalimumab drug antibodies were determined using a drug-resistant assay. Pharmacokinetic data were studied in relation to clinical outcome. Patients who stopped adalimumab by week 12 due to persisting symptoms were considered primary non-responders, whereas initial improvement with increasing symptoms after week 12 was considered loss of response. Adalimumab continuation until the end of follow-up was considered sustained clinical benefit. RESULTS: Patients with low serum levels at week 4 (<8.3 μg/mL) were at significantly higher risk of being anti-adalimumab positive by week 12 (46.7% vs 13.0%, P = 0.009). After a median follow-up of 89 weeks, dose-escalation and sustained clinical benefit were observed in 37.1% and 48.3% of patients. The 21.4% of patients who were anti-adalimumab drug antibody positive by week 12, had a significantly higher need of dose escalation (P < 0.001), and experienced sustained clinical benefit less frequently due to primary non-response or secondary loss of response (P = 0.02). CONCLUSIONS: Our findings support early monitoring of adalimumab serum levels to guide dose optimisation, which may prevent immunogenicity and influence long-term outcome. We validated a novel lateral flow assay for quantitative determination of adalimumab levels, facilitating physicians to optimise therapy immediately at the outpatient clinic.
引用
- Verstockt B, Moors G, Bian S, et al. Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn's disease patients: the usefulness of rapid testing. Aliment Pharmacol Ther. 2018. PMID: 30109889. doi:10.1111/apt.14943
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。